Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Statins Could Reduce Mortality in Some Patients with Arthritis

XTALKS VITALS NEWS

Arthritis

The researchers found that those patients on statin therapy faced a 33 percent lower risk of all-cause mortality, compared to arthritis patients not using the drugs.

Share this!

November 15, 2016 | by Sarah Hand, M.Sc.

While statins are commonly used as cholesterol lowering agents in those at risk of heart disease, heart attack and stroke, a new study suggests that they could also be beneficial to some patients with arthritis. At this year’s American College of Rheumatology Annual Scientific Meeting, researchers from Massachusetts General Hospital in Boston reported that statins reduced mortality in patients with ankylosing spondylitis and psoriatic arthritis.

Ankylosing spondylitis is primarily characterized by inflammation in the joints in the spine, while psoriatic arthritis causes chronic inflammation of the skin and joints. If left untreated, both forms of arthritis can lead to further damage, including bone calcification and joint problems, respectively.

Ankylosing spondylitis and psoriatic arthritis also increase a patient’s risk of death due to cardiovascular disease. While statins have been shown to reduce cholesterol levels, they also have anti-inflammatory properties which promote cardiovascular health.

In order to determine whether statins may reduce mortality in patients with these forms of psoriasis, the researchers analyzed data from a UK database which included nearly 3,000 patients taking statins who were also diagnosed with ankylosing spondylitis or psoriatic arthritis. These patients were compared with the same number of people with these types of arthritis who were not currently taking statins.



After just over five years of follow-up, 271 patients taking statins had died, while 376 patients who were not taking the drug had died. Based on this data, the researchers concluded that those patients on statin therapy faced a 33 percent lower risk of all-cause mortality, compared to arthritis patients not using the drugs.

“Given the increased risk of mortality and cardiovascular disease compared to the general population, patients with seronegative spondyloarthropathies like ankylosing spondylitis or psoriatic arthritis may benefit from the dual anti-inflammatory and lipid-lowering properties of statins, perhaps even more than in the general population,” said Dr. Amar Oza, a rheumatologist at Massachusetts General and a lead author of the study. “This observational study raises the possibility that clinicians may have a lower threshold for starting their patients on statins to mitigate this mortality risk. To that effect, it sets the groundwork for potential clinical trials to come, which will provide high-level evidence about the impact statins have on their health.”

As this conclusion was made based on the results of an observational study, the researchers are unable to say whether the statin therapy is the single cause of the reduced mortality in the arthritis patients. Still, the team believes that the cholesterol-lowering and anti-inflammatory properties of statins could both contribute to their benefit.


Keywords: Statin, Arthritis, Anti-Inflammatory


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News


Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News


Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


Natural History vs. Registry Studies in Rare Disease


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act


Copyright © 2016-2017 Honeycomb Worldwide Inc.